{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-106246","form_type":"8-K","ticker":"APVO","cik":"0001671584","company_name":"Aptevo Therapeutics Inc.","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.602614+00:00","generated_at":"2026-05-17T15:31:44.656711+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aptevo Q2 net loss $6.2M; mipletamig 85% remission in AML; pipeline expands with APVO455","bullets":["Net loss $6.2M for Q2 2025; cash $9.4M as of June 30, 2025.","Raised $15.9M in Q2; extended cash runway into late Q4 2025; secured up to $25M equity line.","Introduced APVO455, a Nectin-4 x CD3 bispecific for bladder, breast, NSCLC, head & neck cancers.","Mipletamig achieved 85% remission rate (11/13) in frontline AML; no CRS reported.","Shares outstanding grew to 3,224,156 vs 72,922 at Dec 31, 2024 due to equity raises."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-106246","json":"https://secwatch.observer/filing/0000950170-25-106246.json","markdown":"https://secwatch.observer/filing/0000950170-25-106246.md","text":"https://secwatch.observer/filing/0000950170-25-106246.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671584/000095017025106246/0000950170-25-106246-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671584/000095017025106246/apvo-20250811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:31:44.656711+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}